Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.43 |
| ▸ | TAF1 | P21675 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 11/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.34 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24617453 | 1.00 | CECR2 (0.43) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL29778613 | 0.83 | MAPK1 (0.39) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL24617466 | 0.83 | MAPK1 (0.39) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL30656477 | 0.83 | GRK2 (0.37) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL29136009 | 0.83 | GRK2 (0.37) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL24617445 | 0.83 | MAPK1 (0.41) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL29778381 | 0.83 | MAPK1 (0.41) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL30656540 | 0.82 | TDO2 (0.40) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL29135965 | 0.82 | TDO2 (0.40) | CECR2TAF1BRD4MAPK1SLC7A5 | |
| SCHEMBL24617451 | 0.82 | BRD4 (0.37) | CECR2TAF1BRD4MAPK1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | Genosco Inc. | 2024-11-14 | — | — | US | claimed |
| CN-117136186-A | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | 盖诺斯克公司 | 2023-11-28 | — | — | CN | claimed |
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | claimed |
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | Genosco Inc. | 2024-11-14 | — | — | US | disclosed |
| CN-117136186-A | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | 盖诺斯克公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | ROCK2, ROCK1, MYLK3 | CECR2 1335/4885TAF1 1323/4885BRD4 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.